

Thymus Chemokine χ 1/CXCL7

Catalog # PVGS1468

Product Information

Primary Accession Species	Q99ME0 Rat
Sequence	Ile46-Ile107
Purity	> 97% as analyzed by SDS-PAGE > 97% as analyzed by HPLC
Endotoxin Level	
Biological Activity	The EC ₅₀ value of rat Thymus Chemokine χ 1/CXCL7 on Ca ²⁺ mobilization assay in CHO-K1/Gα15/rCXCR2 cells (human Gα15 and rat CXCR2 stably expressed in CHO-K1 cells) is less than 300.0 ng/ml.
Expression System	CHO
Formulation	Lyophilized after extensive dialysis against PBS.
Reconstitution	It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH ₂ O or PBS up to 100 μ g/ml.
Storage & Stability	Upon receiving, this product remains stable for up to 6 months at lower than -70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles.

Additional Information

Target Background	Thymus Chemokine χ 1, also called Chemokine (C-X-C motif) ligand 7 (CXCL7), is a member of the CXC chemokines. Similar to other ELR domain containing CXC chemokines such as IL-8 and the GRO proteins, Thymus Chemokine χ 1 has been shown to bind CXCR-2 and be a chemoattractant for neutrophils and play a role in their activation. Although CTAP-III, β -TG and PBP represent amino-terminal extended variants of Thymus Chemokine χ 1 and possess the same CXC chemokine domains, these proteins do not exhibit Thymus Chemokine χ 1 activity. Recently, it has been shown that the additional amino-terminal residues of CTAP-III mask the critical ELR receptor binding domain that is exposed on Thymus Chemokine χ 1 and may account for lack of Thymus Chemokine χ 1 activity. Rat CXCL7 shares 72% amino acid sequence identity with mouse CXCL7.
--------------------------	--

Protein Information

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.